Drug Trial Radar · NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
587
Planned (sponsor's estimate)
Start
May 12, 2025
Primary completion
Oct 2031
Study completion Dec 2032
Sponsor
- Lead sponsor
- Eidos Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Conditions
- Amyloidosis
- Amyloid Cardiomyopathy
- Transthyretin Amyloidosis
- Cardiomyopathies
- Heart Diseases
- Polyneuropathies
Interventions
AcoramidisDrug
TTR stabilizer administered orally twice daily (BID)
Placebo oral tabletDrug
Non-active control administered orally twice daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to development of ATTR (ATTR-CM or ATTR-PN, whichever occurs first; centrally adjudicated)Time frame: Since randomization up to approximately 7 years or until the study is declared over
Locations
104 sites in 24 countries. Site status is shown where the registry gives one.
University of California, San Diego (UCSD) - Medical Center
La Jolla, California · Recruiting
University of California, Los Angeles (UCLA) - David Geffen School of Medicine
Los Angeles, California · Recruiting
University of California, San Francisco (UCSF)
San Francisco, California · Recruiting
Stanford University
Stanford, California · Recruiting
University of Colorado Anschutz
Aurora, Colorado · Recruiting
Yale University School of Medicine - Section of Cardiology
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center - MedStar Heart and Vascular Institute
Washington D.C., District of Columbia · Recruiting
Mayo Clinic - Jacksonville
Jacksonville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Cleveland Clinic Florida
Weston, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois · Recruiting
University of Chicago - Medical Center
Chicago, Illinois · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Boston University (BU) School of Medicine
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
St. Luke's Hospital of Kansas City
Kansas City, Missouri · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey · Recruiting
New York University (NYU) School of Medicine - Langone Medical Center
New York, New York · Recruiting
Mount Sinai Hospital
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Laurelton Heart Specialists
Rosedale, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center, Presbyterian Hospital
Pittsburgh, Pennsylvania · Recruiting
Medical University of South Carolina (MUSC)
Charleston, South Carolina · Recruiting
Prisma Health Cancer Institute
Greenville, South Carolina · Recruiting
National Neuromuscular Research Institute
Austin, Texas · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
INOVA Fairfax Hospital
Falls Church, Virginia · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.